Statements (45)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:chemical_compound
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Sodium_Oxybate
|
| gptkbp:affects |
CNS depressant
|
| gptkbp:brand |
gptkb:Xyrem
Alcover |
| gptkbp:common_name |
gptkb:GHB
|
| gptkbp:composed_of |
can be synthesized from gamma-butyrolactone
|
| gptkbp:discovered_by |
in the 1960s
|
| gptkbp:dissolved |
soluble in water
soluble in alcohol |
| https://www.w3.org/2000/01/rdf-schema#label |
gamma-hydroxybutyrate
|
| gptkbp:ingredients |
C4 H8 O3
|
| gptkbp:is_atype_of |
N05 C D01
|
| gptkbp:legal_issue |
controlled substance in many countries
|
| gptkbp:level |
4.0
|
| gptkbp:manager |
oral
intravenous |
| gptkbp:melting_point |
-20 ° C (-4 ° F)
200 ° C (392 ° F) |
| gptkbp:metabolism |
converted to succinic semialdehyde
|
| gptkbp:previous_name |
gptkb:4-hydroxybutanoic_acid
|
| gptkbp:products |
gptkb:1,4-butanediol
gptkb:gamma-butyrolactone |
| gptkbp:research_areas |
sleep disorders
anxiety disorders muscle growth memory enhancement alcohol dependence |
| gptkbp:safety_features |
risk of addiction
risk of overdose not safe for use with alcohol not safe for use with other depressants should be used under medical supervision |
| gptkbp:side_effect |
gptkb:archaeological_site
nausea confusion drowsiness respiratory depression |
| gptkbp:treatment |
GHB overdose
GHB withdrawal |
| gptkbp:type_of |
501-61-8
|
| gptkbp:uses |
gptkb:healthcare_organization
treatment for narcolepsy recreational drug |